Fig. 4From: Predicting the prognosis, immune response, and immunotherapy in head and neck squamous cell carcinoma using a novel risk model based on anoikis-related lncRNAsPCA analysis of the data derived from the entire cohort. The results of the PCA analyses indicated that the D anoikis-related lncRNA signature could be differentiated based on the risk status of HNSCC patients compared to the A whole genome, B anoikis-related gene and C anoikis-related lncRNABack to article page